Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03066648
Title Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals

acute myeloid leukemia

myelodysplastic syndrome


Decitabine + Spartalizumab

Decitabine + Sabatolimab + Spartalizumab

Decitabine + Sabatolimab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.